| Pair                        | Median [lower, upper] |
|---------------------------|-----------------------|
| TR_BPO_MTCAM vs TA_BPO_Lasers | −26.31 [−41.12, −11.65] |
| TR_BPO_MTCAM vs TA_TR_MTCAM | −11.10 [−14.61, −7.75] |
| TR_BPO_MTCAM vs TA_BPO_OA | −10.73 [−18.57, −3.59] |
| TR_BPO_MTCAM vs TR_MTCAM  | −13.58 [−23.00, −4.45] |
| TA_TR_MTCAM vs TA_MTCAM   | −11.47 [−21.09, −1.78] |
| TR_BPO_MTCAM vs OA_PDT    | −16.60 [−31.06, −2.03] |
| TA_BPO_Lasers vs Placebo  | −17.38 [−29.46, −4.87] |
| TA_BPO_CP vs TR_BPO_OA    | −14.56 [−28.66, −0.25] |
| Lasers_PDT vs LED_MTCAM   | −14.03 [−22.03, −5.45] |
| TA_MTCAM vs LED_MTCAM     | −10.66 [−46.56, 30.22] |
| TA_TR_MTCAM vs TA_BPO     | −11.47 [−21.09, −1.78] |
| TR_BPO_Lasers vs CP       | −17.38 [−29.46, −4.87] |
| TA_BPO_Lasers vs TR       | −14.56 [−28.66, −0.25] |
| TR_BPO_OA vs MTCAM        | −14.03 [−22.03, −5.45] |
| TR_BPO vs Lasers_PDT      | −10.66 [−46.56, 30.22] |
| TR_BPO_MTCAM vs TR        | −11.47 [−21.09, −1.78] |
| TR_BPO_MTCAM vs TA        | −11.47 [−21.09, −1.78] |
| TR_BPO_OA vs TA_MTCAM     | −17.38 [−29.46, −4.87] |
| TR_BPO vs Placebo         | −17.38 [−29.46, −4.87] |
| TR_BPO_OA vs CP           | −17.38 [−29.46, −4.87] |
| TR_BPO vs IPL             | −17.38 [−29.46, −4.87] |
| TA_BPO vs TR_OA           | −17.38 [−29.46, −4.87] |
| TR_BPO vs IPL             | −17.38 [−29.46, −4.87] |
| TA_BPO vs IPL             | −17.38 [−29.46, −4.87] |
| BPO_MTCAM vs TD           | −17.38 [−29.46, −4.87] |
| LED vs OA                 | −17.38 [−29.46, −4.87] |
| TD vs OA                  | −17.38 [−29.46, −4.87] |
| CP vs TD                  | −17.38 [−29.46, −4.87] |
| TR_BPO vs OA_PDT          | −17.38 [−29.46, −4.87] |
| TR_BPO_OA vs CP           | −17.38 [−29.46, −4.87] |
| TR_BPO vs MTCAM           | −17.38 [−29.46, −4.87] |
| TA_BPO_CP vs TT           | −17.38 [−29.46, −4.87] |
| MTCAM vs TR_OA            | −17.38 [−29.46, −4.87] |
| TA_TR vs TR_OA            | −17.38 [−29.46, −4.87] |
| TR_BPO vs IPL             | −17.38 [−29.46, −4.87] |
| IPL vs Placebo            | −17.38 [−29.46, −4.87] |
| TT vs Placebo             | −17.38 [−29.46, −4.87] |
| TR_OA vs IPL              | −17.38 [−29.46, −4.87] |
| TR_BPO_OA vs TR           | −17.38 [−29.46, −4.87] |
| TR_BPO_OA vs TA           | −17.38 [−29.46, −4.87] |
| BPO vs TD                 | −17.38 [−29.46, −4.87] |
| LED vs OA                 | −17.38 [−29.46, −4.87] |
| TD vs OA                  | −17.38 [−29.46, −4.87] |
| CP vs TD                  | −17.38 [−29.46, −4.87] |
| Study         | Mean Difference (95% CrI) | P-value | network       | Direct | Indirect | Network |
|---------------|---------------------------|---------|---------------|--------|----------|---------|
| CP vs BPO     |                           |         |               |        |          |         |
| direct        | 1.0 (−7.9, 9.8)           | 1.0     | 3.5 (−2.1, 9.8) | 2.7 (−1.8, 7.8) |         |
| network       | 6.9 (−18.3, 9.3)          | 0.0779  | 6.2 (−2.2, 16) | 0.27 (−2.7, 7.7) |         |
| direct        | 0.00345                   | 0.49 (−5.5, 4.4) | 6.5 (−2.6, 17) | 0.7 (−3.8, 4.9) |         |
| network       | 3.4 (−11.9, 8.2)          | 0.00055 | 2.0 (−2.3, 6.2) | 0.0 (−0.1, 0.1) |         |
| Placido vs BPO| 17.1 (11.2, 23.1)         | 0.00055 | 3.6 (−0.1, 8.2) | 7.8 (4.7, 14.3) |         |
| direct        | 2.4 (−12.1, 16.9)         | 0.0545  | 3.5 (−2.1, 9.8) | 2.7 (−1.9, 7.8) |         |
| network       | 0.6316                    | 0.0036  | 0.6 (−2.1, 9.8) | 0.2 (−1.8, 6.2) |         |
| LED vs CP     | 0.0776                    | 0.56    | 2.0 (−6.7, 11) | 0.25 (−5.8, 4.8) |         |
| network       | 0.64 (−12.1, 14.8)        | 0.0085  | 1.8 (−12.1, 15.1) | 3.3 (−1.9, 5.1) |         |
| Placido vs CP | 0.06                        | 1.0     | 0.5 (−2.1, 9.7) | 0.2 (−1.8, 6.2) |         |
| network       | 0.00345                    | 0.0014  | 0.2 (−1.8, 6.2) | 0.0 (−0.1, 0.1) |         |
| LED vs CP     | 0.00955                   | 0.56    | 2.0 (−6.7, 11) | 0.25 (−5.8, 4.8) |         |
| network       | 0.64 (−12.1, 14.8)        | 0.0085  | 1.8 (−12.1, 15.1) | 3.3 (−1.9, 5.1) |         |
| Placido vs CP | 0.06                        | 1.0     | 0.5 (−2.1, 9.7) | 0.2 (−1.8, 6.2) |         |
| network       | 0.00345                    | 0.0014  | 0.2 (−1.8, 6.2) | 0.0 (−0.1, 0.1) |         |
| MTCAM vs BPO  | 0.0776                    | 0.56    | 2.0 (−6.7, 11) | 0.25 (−5.8, 4.8) |         |
| network       | 0.64 (−12.1, 14.8)        | 0.0085  | 1.8 (−12.1, 15.1) | 3.3 (−1.9, 5.1) |         |
| Placido vs CP | 0.06                        | 1.0     | 0.5 (−2.1, 9.7) | 0.2 (−1.8, 6.2) |         |
| network       | 0.00345                    | 0.0014  | 0.2 (−1.8, 6.2) | 0.0 (−0.1, 0.1) |         |
| Placebo vs CP | 0.0776                    | 0.56    | 2.0 (−6.7, 11) | 0.25 (−5.8, 4.8) |         |
| network       | 0.64 (−12.1, 14.8)        | 0.0085  | 1.8 (−12.1, 15.1) | 3.3 (−1.9, 5.1) |         |
| Placebo vs CP | 0.06                        | 1.0     | 0.5 (−2.1, 9.7) | 0.2 (−1.8, 6.2) |         |
| network       | 0.00345                    | 0.0014  | 0.2 (−1.8, 6.2) | 0.0 (−0.1, 0.1) |         |
| Placebo vs CP | 0.0776                    | 0.56    | 2.0 (−6.7, 11) | 0.25 (−5.8, 4.8) |         |
| network       | 0.64 (−12.1, 14.8)        | 0.0085  | 1.8 (−12.1, 15.1) | 3.3 (−1.9, 5.1) |         |
| Placebo vs CP | 0.06                        | 1.0     | 0.5 (−2.1, 9.7) | 0.2 (−1.8, 6.2) |         |
| network       | 0.00345                    | 0.0014  | 0.2 (−1.8, 6.2) | 0.0 (−0.1, 0.1) |         |
### Non-inflammatory lesions

| StudyID        | 95%CI         | P-value |
|---------------|--------------|---------|
| Appiah 2017   | (-18.09, -1.06) | 0.03    |
| Bissonnette 2016 | (-19.81, -1.78) | 0.02    |
| Capitanio 2012 | (-19.28, -1.51) | 0.02    |
| Charakida 2007 | (-12.54, -0.82) | 0.03    |
| Jung 2014a    | (-19.83, -1.99) | 0.02    |
| Jung 2014b    | (-19.9, -2.16)  | 0.01    |
| Lu 2016       | (-20.09, -3.05) | 0.01    |
| Mohebbipour 2015 | (-20.08, -3.15) | 0.01    |
| Papageorgiou 2000 | (-13.98, -0.69) | 0.03    |

### Inflammatory lesions

| StudyID        | 95%CI         | P-value |
|---------------|--------------|---------|
| Appiah 2017   | (-9.87, -1.1)  | 0.014   |
| Bissonnette 2016 | (-9.55, -0.79) | 0.021   |
| Capitanio 2012 | (-10.52, -1.6) | 0.008   |
| Charakida 2007 | (-6.14, -0.72) | 0.013   |
| Jung 2014a    | (-10.25, -1.09) | 0.015   |
| Jung 2014b    | (-10.35, -1.27) | 0.012   |
| Lu 2016       | (-10.31, -1.59) | 0.007   |
| Mohebbipour 2015 | (-10.54, -2.57) | 0.001   |
| Papageorgiou 2000 | (-9.51, -0.72)  | 0.023   |
| Study | Mean Difference (95% CrI) | P−value |
|-------|--------------------------|---------|
| **CP vs BPO** | | |
| direct | 5.0 (−5.8, 6.9) | 0.10335 |
| indirect | 3.0 (−4.3, 10.1) | 0.5764 |
| **LED vs BPO** | | |
| direct | 4.1 (−0.53, 8.9) | 0.50745 |
| indirect | 3.8 (−1.5, 10.2) | 0.26365 |
| **MTCAM vs BPO** | | |
| direct | 4.1 (−0.53, 8.9) | 0.6935 |
| indirect | 3.8 (−1.5, 10.2) | 0.2636 |
| **Placebo vs BPO** | | |
| direct | 5.0 (−5.8, 6.9) | 0.10335 |
| indirect | 3.0 (−4.3, 10.1) | 0.5764 |
| **TA_BPO vs BPO** | | |
| direct | 4.1 (−0.53, 8.9) | 0.6935 |
| indirect | 3.8 (−1.5, 10.2) | 0.2636 |
| **TR vs BPO** | | |
| direct | 5.0 (−5.8, 6.9) | 0.10335 |
| indirect | 3.0 (−4.3, 10.1) | 0.5764 |
| **LED vs CP** | | |
| direct | 4.1 (−0.53, 8.9) | 0.6935 |
| indirect | 3.8 (−1.5, 10.2) | 0.2636 |
| **Placebo vs CP** | | |
| direct | 5.0 (−5.8, 6.9) | 0.10335 |
| indirect | 3.0 (−4.3, 10.1) | 0.5764 |
| **TA_BPO vs CP** | | |
| direct | 4.1 (−0.53, 8.9) | 0.6935 |
| indirect | 3.8 (−1.5, 10.2) | 0.2636 |
| **Lasers_PDT vs Lasers** | | |
| direct | 4.1 (−0.53, 8.9) | 0.6935 |
| indirect | 3.8 (−1.5, 10.2) | 0.2636 |
| **Placebo vs Lasers** | | |
| direct | 5.0 (−5.8, 6.9) | 0.10335 |
| indirect | 3.0 (−4.3, 10.1) | 0.5764 |
| **PDT vs Lasers_PDT** | | |
| direct | 4.1 (−0.53, 8.9) | 0.6935 |
| indirect | 3.8 (−1.5, 10.2) | 0.2636 |
| **TR vs OA** | | |
| direct | 5.0 (−5.8, 6.9) | 0.10335 |
| indirect | 3.0 (−4.3, 10.1) | 0.5764 |
| **TR_OA vs OA** | | |
| direct | 5.0 (−5.8, 6.9) | 0.10335 |
| indirect | 3.0 (−4.3, 10.1) | 0.5764 |
| **TA vs OA** | | |
| direct | 5.0 (−5.8, 6.9) | 0.10335 |
| indirect | 3.0 (−4.3, 10.1) | 0.5764 |
| **TA_MTCAM vs TA** | | |
| direct | 5.0 (−5.8, 6.9) | 0.10335 |
| indirect | 3.0 (−4.3, 10.1) | 0.5764 |
| **TA_TR vs TA** | | |
| direct | 5.0 (−5.8, 6.9) | 0.10335 |
| indirect | 3.0 (−4.3, 10.1) | 0.5764 |
| **TR_OA vs OA** | | |
| direct | 5.0 (−5.8, 6.9) | 0.10335 |
| indirect | 3.0 (−4.3, 10.1) | 0.5764 |
| **TA vs Placebo** | | |
| direct | 5.0 (−5.8, 6.9) | 0.10335 |
| indirect | 3.0 (−4.3, 10.1) | 0.5764 |
| **TA_BPO vs Placebo** | | |
| direct | 5.0 (−5.8, 6.9) | 0.10335 |
| indirect | 3.0 (−4.3, 10.1) | 0.5764 |
| **TA_TR vs Placebo** | | |
| direct | 5.0 (−5.8, 6.9) | 0.10335 |
| indirect | 3.0 (−4.3, 10.1) | 0.5764 |
| **TR vs Placebo** | | |
| direct | 5.0 (−5.8, 6.9) | 0.10335 |
| indirect | 3.0 (−4.3, 10.1) | 0.5764 |
| **TA_BPO vs TA** | | |
| direct | 5.0 (−5.8, 6.9) | 0.10335 |
| indirect | 3.0 (−4.3, 10.1) | 0.5764 |
| **TA_MTCAM vs TA** | | |
| direct | 5.0 (−5.8, 6.9) | 0.10335 |
| indirect | 3.0 (−4.3, 10.1) | 0.5764 |
| **TR vs TA** | | |
| direct | 5.0 (−5.8, 6.9) | 0.10335 |
| indirect | 3.0 (−4.3, 10.1) | 0.5764 |
| **TA_MTCAM vs TA_BPO** | | |
| direct | 5.0 (−5.8, 6.9) | 0.10335 |
| indirect | 3.0 (−4.3, 10.1) | 0.5764 |
| **TR vs TA_BPO** | | |
| direct | 5.0 (−5.8, 6.9) | 0.10335 |
| indirect | 3.0 (−4.3, 10.1) | 0.5764 |
| **TA_MTCAM vs TA_TR** | | |
| direct | 5.0 (−5.8, 6.9) | 0.10335 |
| indirect | 3.0 (−4.3, 10.1) | 0.5764 |
| **TR vs TA_TR** | | |
| direct | 5.0 (−5.8, 6.9) | 0.10335 |
| indirect | 3.0 (−4.3, 10.1) | 0.5764 |
### A: Bayesian NMA

| Treatment      | Risk Ratio (95% CI) |
|----------------|---------------------|
| BPO            | 1.5 (1.1, 2.2)      |
| BPO_MTCAM      | 5.3 (1.1, 4.2)      |
| CP             | 2.2 (1.3, 4.1)      |
| Lasers         | 1.3 (0.31, 9.4)     |
| LED            | 1.5e+11 (11., 8.1e+37)|
| MTCAM          | 1.2 (0.72, 2.1)     |
| OA             | 6.6 (2.4, 19.)      |
| OA_PDT         | 16. (3.9, 70.)      |
| PDT            | 3.6 (1.4, 12.)      |
| TA             | 0.86 (0.63, 1.1)    |
| TA_BPO         | 1.6 (1.2, 2.2)      |
| TA_BPO_CP      | 2.1 (1.0, 4.2)      |
| TA_MTCAM       | 1.3 (0.65, 2.7)     |
| TA_TR          | 2.5 (1.8, 3.6)      |
| TD             | 0.97 (0.56, 1.7)    |
| TN             | 1.0 (0.42, 2.5)     |
| TR             | 2.7 (2, 3.7)        |
| TR_BPO         | 3.1 (2.2, 5.9)      |
| TR_BPO_OA      | 8. (2.2, 30.)       |
| TR_MTCAM       | 3.1 (1.8, 5.5)      |
| TR_OA          | 4.7 (2.1, 11.)      |
| TT             | 1.2 (0.60, 2.3)     |

### B: Frequentist NMA

| Treatment       | Comparison: other vs 'Placebo' (Random Effects Model) | RR    | 95%-CI  |
|-----------------|------------------------------------------------------|-------|--------|
| BPO             | Standard NMA                                         | 1.56  | [1.14, 2.14] |
|                 | Additive NMA                                         | 1.53  | [1.27, 1.86] |
|                 | BPO+MTCAM                                            | 4.31  | [0.85, 21.92] |
|                 | Standard NMA                                         | 1.90  | [1.29, 2.81] |
|                 | Additive NMA                                         | 2.21  | [1.34, 3.64] |
|                 | LED                                                  | 1.62  | [1.03, 2.55] |
|                 | Standard NMA                                         | 0.97  | [0.22, 4.29] |
|                 | Additive NMA                                         | 0.97  | [0.21, 4.53] |
|                 | MTCAM                                                | 7.00  | [0.36, 135.72] |
|                 | Standard NMA                                         | 1.01  | [0.83, 1.21] |
|                 | Additive NMA                                         | 1.24  | [0.89, 1.72] |
|                 | OA                                                    | 6.82  | [2.57, 18.13] |
|                 | Additive NMA                                         | 1.98  | [0.86, 4.37] |
|                 | PDT                                                   | 17.81 | [4.59, 69.10] |
|                 | Standard NMA                                         | 5.77  | [1.96, 16.69] |
|                 | Additive NMA                                         | 3.29  | [1.24, 8.69] |
|                 | TA                                                   | 2.92  | [1.40, 6.06] |
|                 | Standard NMA                                         | 0.88  | [0.68, 1.14] |
|                 | Additive NMA                                         | 0.92  | [0.74, 1.14] |
|                 | TA_BPO                                               | 1.72  | [1.32, 2.25] |
|                 | Additive NMA                                         | 1.41  | [1.08, 1.84] |
|                 | TA+BPO                                               | 2.22  | [1.25, 3.84] |
|                 | Additive NMA                                         | 2.28  | [1.28, 4.06] |
|                 | TA+MTCAM                                             | 1.48  | [0.76, 2.88] |
|                 | Additive NMA                                         | 1.14  | [0.77, 1.69] |
|                 | TA+TR                                                | 2.72  | [1.99, 3.73] |
|                 | Additive NMA                                         | 2.02  | [1.47, 2.77] |
|                 | TR                                                   | 0.97  | [0.64, 1.49] |
|                 | Additive NMA                                         | 0.97  | [0.54, 1.75] |
|                 | Standard NMA                                         | 1.12  | [0.49, 2.52] |
|                 | Additive NMA                                         | 1.17  | [0.48, 2.87] |
|                 | TR+MTCAM                                             | 2.83  | [2.13, 3.76] |
|                 | Additive NMA                                         | 2.19  | [1.76, 2.74] |
|                 | Standard NMA                                         | 3.85  | [2.57, 5.77] |
|                 | Additive NMA                                         | 3.37  | [2.46, 4.66] |
|                 | TR+BPO                                               | 6.52  | [2.50, 29.04] |
|                 | Additive NMA                                         | 6.65  | [2.83, 15.64] |
|                 | TR+MTCAM                                             | 3.36  | [2.03, 5.54] |
|                 | Additive NMA                                         | 2.72  | [1.83, 4.04] |
|                 | TR+OA                                                | 5.38  | [2.42, 11.97] |
|                 | Additive NMA                                         | 4.33  | [1.90, 9.90] |
|                 | Tr                                                    | 1.18  | [0.68, 2.08] |
|                 | Additive NMA                                         | 1.10  | [0.58, 2.26] |
| Study                  | P-value             | Risk Ratio (95% CrI)  |
|-----------------------|---------------------|-----------------------|
| **MTCAM vs BPO**      |                     |                       |
| direct                | 0.3477              | 0.27 (0.004, 2.4)     |
| indirect              |                     | 0.85 (0.80, 1.9)      |
| network               |                     | 0.78 (0.42, 1.6)      |
| **Placebo vs BPO**    |                     |                       |
| direct                | 0.197               | 0.79 (0.45, 1.3)      |
| indirect              |                     | 0.43 (0.19, 1.0)      |
| network               |                     | 0.65 (0.45, 0.95)     |
| **TA vs BPO**         |                     |                       |
| direct                | 0.2982              | 0.71 (0.35, 1.5)      |
| indirect              |                     | 0.49 (0.30, 0.81)     |
| network               |                     | 0.56 (0.38, 0.82)     |
| **TA_BPO vs BPO**     |                     |                       |
| direct                | 0.3679              | 0.89 (0.56, 1.4)      |
| indirect              |                     | 1.2 (0.69, 2.1)       |
| network               |                     | 1.1 (0.74, 1.5)       |
| **TR vs BPO**         |                     |                       |
| direct                | 0.2686              | 1.8 (0.94, 3.4)       |
| indirect              | 0.0617              | 1.7 (0.97, 2.9)       |
| network               | 1.7 (1.2, 2.6)      |                       |
| **TR_BPO vs BPO**     |                     |                       |
| direct                | 0.599               | 2.5 (1.3, 4.7)        |
| indirect              |                     | 1.5 (0.32, 12.)       |
| network               |                     | 2.4 (1.4, 3.9)        |
| **Placebo vs CP**     |                     |                       |
| direct                | 0.0245              | 6.1e–09 (0.8–31, 0.31) |
| indirect              |                     | 0.47 (0.17, 1.3)      |
| network               | 0.40 (0.14, 1.1)    |                       |
| **TA vs Placebo**     |                     |                       |
| direct                | 0.7258              | 0.82 (0.46, 1.5)      |
| indirect              |                     | 0.80 (0.30, 1.3)      |
| network               | 0.85 (0.63, 1.2)    |                       |
| **TA_BPO vs Placebo** |                     |                       |
| direct                | 0.0537              | 1.1 (0.71, 1.8)       |
| indirect              |                     | 2.0 (1.4, 2.9)        |
| network               | 1.6 (1.2, 2.2)      |                       |
| **TR vs Placebo**     |                     |                       |
| direct                | 0.4607              | 1.8 (0.77, 4.6)       |
| indirect              |                     | 2.6 (1.7, 3.9)        |
| network               | 2.5 (1.7, 3.6)      |                       |
| **TA_BPO vs TA**      |                     |                       |
| direct                | 0.5491              | 2.8 (1.9, 4.3)        |
| indirect              |                     | 2.3 (1.2, 4.1)        |
| network               | 2.7 (2.3, 3.7)      |                       |
| **TR vs TA**          |                     |                       |
| direct                | 0.3004              | 1.5 (1.5, 2.8)        |
| indirect              |                     | 1.8 (1.0, 2.5)        |
| network               | 1.9 (1.5, 2.5)      |                       |
| **TA_MTCAM vs TA**    |                     |                       |
| direct                | 0.963               | 1.5 (0.57, 3.9)       |
| indirect              |                     | 1.6 (0.60, 4.3)       |
| network               | 1.5 (0.78, 3.0)     |                       |
| **TA_TR vs TA**       |                     |                       |
| direct                | 0.321               | 2.4 (1.4, 4.1)        |
| indirect              |                     | 3.4 (2.1, 5.5)        |
| network               | 2.9 (2.1, 4.1)      |                       |
| **TR vs TA**          |                     |                       |
| direct                | 0.675               | 3.4 (1.8, 6.2)        |
| indirect              |                     | 2.9 (1.9, 4.6)        |
| network               | 3.1 (2.2, 4.4)      |                       |
| **TA_MTCAM vs TA_BPO**|                     |                       |
| direct                | 0.9169              | 0.83 (0.32, 2.1)      |
| indirect              |                     | 0.77 (0.29, 2.1)      |
| network               | 0.90 (0.40, 1.6)    |                       |
| **TA_TR vs TA_BPO**   |                     |                       |
| direct                | 0.9986              | 1.5 (0.95, 2.4)       |
| indirect              |                     | 1.5 (0.96, 2.4)       |
| network               | 1.5 (1.1, 2.1)      |                       |
| **TR vs TA_BPO**      |                     |                       |
| direct                | 0.8394              | 1.5 (0.50, 4.5)       |
| indirect              |                     | 1.6 (1.2, 2.3)        |
| network               | 1.6 (1.2, 2.3)      |                       |
| **TR vs TA_TR**       |                     |                       |
| direct                | 0.279               | 0.94 (0.63, 1.4)      |
| indirect              |                     | 1.4 (0.74, 2.8)       |
| network               | 1.1 (0.78, 1.5)     |                       |
| **TR_BPO vs TR**      |                     |                       |
| direct                | 0.6369              | 1.4 (0.76, 2.6)       |
| indirect              |                     | 0.89 (0.55, 1.6)      |
| network               | 1.4 (0.81, 2.2)     |                       |
